HCW Biologics

The Development of Natural Killer Cells for Solid Tumor Treatment March 29, 2021 In The News Wugen Announces Exclusive License Agreement With HCW Biologics

HCW Biologics Inc. (Nasdaq: HCWB) is a clinical stage biopharmaceutical company developing first-in-class immunotherapies to revolutionize the treatments for

Phone: (954) 842-2024Fax: (954) 842-2037Email: info@hcwbiologics.com

The page describes fusion immunotherapeutics as treatments for autoimmune diseases, cancer and senescence-associated dysplasia.

HCW Biologics receives clear FDA guidance during a recent Type B meeting to finalize its Investigational New Drug (IND) application. The company aims to support its first-in-human clinical study evaluating a lead T-cell engager therapy for treating solid tumors. The meeting helps align the IND submission with regulatory expectations for progression.

Oct 2026GlobeNewswireNews article

HCW Biologics Inc. raises **$1.5 million** through a private placement to advance its clinical-stage biologic therapies. The company, listed on NASDAQ under **HCWB**, focuses on developing treatments in the biologics space. This funding supports ongoing research and operational growth.

Sep 2026GlobeNewswireNews article

HCW Biologics partners with Akron Biotech to exclusively distribute **HCW11-006**, a second-generation multi-cytokine reagent supporting production of highly functional human **CAR-T cells**. The agreement includes pre-payment commitments for sales and distribution, targeting advanced cell therapy manufacturing.

Sep 2026GlobeNewswireNews article

HCW Biologics expands its U.S. patent protections for **HCW9302**, an IL-2-based immunotherapeutic targeting alopecia areata by modulating regulatory T cells. The company’s lead clinical-stage asset aims to treat autoimmune diseases through immune system activation. HCW9302 is positioned as a best-in-class candidate in its therapeutic class.

Sep 2026GlobeNewswireNews article